Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-05-09
Target enrollment:
Participant gender:
Summary
Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel
chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and
locally advanced unresectable pancreatic cancer patients with sequential investigator
selection (IC).